AI Meets Precision Medicine: How Nucleai is Advancing Antibody-Drug Conjugates Development
Antibody-drug conjugates (ADCs) are quickly emerging as one of the most promising innovations in targeted cancer therapy—offering the potential to deliver powerful drugs directly to cancer cells with fewer side effects. But unlocking their full potential requires a deep understanding of who they work for and why.
That’s where Nucleai comes in.
In a recent interview with Technology Networks, Dr. Jason Reeves, Director of Application Science at Nucleai, explained how the company is using AI and spatial biomarkers to guide Antibody-Drug Conjugates development and bring more precise, personalized cancer treatments to the clinic.
AI + Spatial Biology = Smarter Drug Development
Nucleai’s platform analyzes tissue samples with unmatched precision, using advanced AI to uncover spatial patterns that reveal how patients’ immune systems interact with tumors. These insights enable biopharma companies to better stratify patients, ensuring that ADCs are delivered to those most likely to benefit.
Key highlights from the interview:
- How spatial biomarkers offer a new dimension of insight into tumor biology
- Why ADCs represent a major leap forward in precision oncology
- The critical role of AI in identifying the right patients and accelerating drug discovery
A New Era for Precision Oncology
By partnering with leading biopharma companies, Nucleai is helping to bring next-generation therapies to market faster—and with greater confidence. The result? More targeted, effective, and personalized cancer treatments for patients who need them most.
📌 Read the full interview on Technology Networks:
🔗 How AI and Spatial Biomarkers Are Transforming ADC Development